Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel In Prevention Of BCCs In Patients With Gorlin Syndrome

NCT04893486 is registered in ClinicalTrials.gov with Palvella Therapeutics, Inc. as lead sponsor.

NCT NCT04893486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04893486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel In Prevention Of BCCs In Patients With Gorlin Syndrome
Lead sponsor
Palvella Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2021
Completion date
March 13, 2023
Enrollment
73 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bccs in gorlin syndrome patients